Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In recent years, mergers and acquisitions have seen a record number of transactions and ...

According to the Harvard Business Review, approximately 70% to 90% of all mergers and acquisitions (M&A) fail to meet the expected goals and synergies. Mergers and acquisitions often fail in ...

CHAPEL HILL, N.C., April 28 /PRNewswire/ -- The biopharma mega-mergers that grabbed headlines last year - Roche + Genentech, Pfizer + Wyeth and Merck + Schering-Plough - are now in the critical ...

Beyond the pure play of the financial transaction, virtually every merger and/or acquisition is an arduous journey upon which to embark with the potential of every challenge, from cultural clashes to ...

Merger activity across healthcare increased significantly in 2015 and is continuing to accelerate according to the Wall Street Journal 1. The pace is fueled by many factors, both general and unique to ...

Opinion: Navigating global M&A requires patience and learning how to bridge gaps. It also helps to prioritize human elements, ...

With tens of billions of dollars of “dry powder” at the ready for deployment in big national public builders’ coffers, NDAs, MOUs, and LOIs are a thing right now. At the same time, a veritable “Four ...

Successful M&As don’t succeed by leadership vision alone. They require clear and concise goals executed by a focused and purposeful workforce. Actually, two workforces. And with an M&A, there is the ...

TCF Financial in Minneapolis and Chemical Financial in Detroit had prepared for a daunting integration as part of their $3.6 billion merger. They underestimated the challenge. The $50 billion-asset ...

As capital remains cheap and competition increases, more and more corporate finance strategists are willing to take on transformational deals. Unlike absorption deals, in which companies acquire ...

CHAPEL HILL, N.C., April 28 /PRNewswire/ -- The biopharma mega-mergers that grabbed headlines last year - Roche + Genentech, Pfizer + Wyeth and Merck + Schering-Plough - are now in the critical ...